Colorectal cancer screening: a global overview of existing programmes

Eline H Schreuders,1 Arlinda Ruco,2 Linda Rabeneck,3,4,5,6,7 Robert E Schoen,8 Joseph J Y Sung,9 Graeme P Young,10 Ernst J Kuipers1

ABSTRACT
Colorectal cancer (CRC) ranks third among the most commonly diagnosed cancers worldwide, with wide geographical variation in incidence and mortality across the world. Despite proof that screening can decrease CRC incidence and mortality, CRC screening is only offered to a small proportion of the target population worldwide. Throughout the world there are widespread differences in CRC screening implementation status and strategy. Differences can be attributed to geographical variation in CRC incidence, economic resources, healthcare structure and infrastructure to support screening such as the ability to identify the target population at risk and cancer registry availability. This review highlights issues to consider when implementing a CRC screening programme and gives a worldwide overview of CRC burden and the current status of screening programmes, with focus on international differences.

BACKGROUND
Worldwide colorectal cancer (CRC) is the third most common cancer in men (746 000 cases, 10.0% of the total) and the second in women (614 000 cases, 9.2% of the total).1 There is however wide geographical variation in CRC incidence and mortality, with very similar patterns in men and women. The age-standardised incidence rates (ASRs) vary 10-fold in both sexes worldwide. When comparing world regions as classified by the United Nations, the highest estimated rates occur in the Australia/New Zealand region (ASR 44.8 per 100 000 and 32.2 per 100 000 in men and women, respectively), and the lowest in western Africa (4.5 per 100 000 and 3.8 per 100 000). Almost 55% of CRC cases occur in more developed regions.1 However, in many developing countries (including some parts of Africa), there is the possibility of under-reporting because cancer registries are lacking or have incomplete coverage. Large disparities exist between high-income and low-income countries in the proportion of their populations covered by cancer registries.7 The lifetime risk of developing CRC in many regions is around 5%. Approximately 45% of persons diagnosed with CRC die as a result of the disease, despite treatment.1 Treatment modalities have largely improved over the past decade. Treatment has modestly improved disease outcome and extended survival in patients with advanced and metastatic disease. But, these advancements have been accompanied by markedly increased treatment costs. As a result, modelling studies have shown that various screening strategies are cost-saving.4 Most CRCs develop from a preclinical precursor, the adenoma. The progression from early adenoma to invasive cancer takes years.5 The high incidence, long preclinical phase, recognisable and treatable precursor, the high cost of treatment, and the correlation of mortality with disease stage make CRC highly suitable for population screening.5 7 9 This has been confirmed by randomised controlled trials (RCTs) that have formed the basis for international guidelines recommending CRC screening.10–13 Despite these recommendations, screening is currently only offered to a small proportion of the target population.

The goal of this review is to address various aspects to consider for implementing a successful screening programme and to give an overview of screening programmes worldwide, with a focus on international differences.

METHODS
For this review, national and international guidelines on CRC screening were evaluated. We collected information on CRC screening programme characteristics from guidelines, through national governmental websites and international contact persons including public health researchers,
those responsible for the development and implementation of screening programmes and participants of the Colorectal Cancer Screening Committee of the World Endoscopy Organisation. A literature search in PUBMED and The Cochrane Central Register of Controlled Trials was performed using the following keywords: CRC screening, guidelines, Europe/ America/ Canada/ Asia/ Australia/ New Zealand, RCTs, colonoscopy, guaiac faecal occult blood test (gFOBT), faecal immunochemical test for haemoglobin (FIT), flexible sigmoidoscopy (FS), CT colonography (CTC), DNA-marker and video capsule endoscopy. To evaluate and compare screening programmes, we used the universally applicable CRC screening indicators established by the International Colorectal Cancer Screening Network based on the criteria of the International Agency for Research on Cancer (IARC). To report screening indicators regarding screening programmes and participants of the Colorectal Cancer Evaluation Reporting guidelines were followed. We used the recommended reporting units of microgram haemoglobin per gram faeces (µg Hb/g) rather than nanogram haemoglobin per millilitre buffer (ng Hb/mL) to ensure comparability of results. The term ‘average risk population’ used in this review refers to an asymptomatic population who is at average risk for CRC. The age range of this population is influenced by national guidelines and varies per study but is mainly over age 50 years and constantly over age 40 years. For the overview of current status of screening programmes, at least the top 10 countries with highest age-ASRs for each world continent were included.

SCREENING METHODS

Detection and removal of cancer precursors can reduce CRC incidence and mortality. Early detection of CRC allows less invasive treatment, with lower morbidity, mortality and treatment cost. The implementation of a CRC screening programme requires that strategic decisions be addressed. One is the selection of a screening modality, which can be a non-invasive test or an invasive test.

Non-invasive stool tests

Non-invasive stool tests include gFOBTs and FITs. These inexpensive tests detect microscopic amounts of blood by targeting either haem (gFOBTs) or human globin (FITs). A meta-analysis of four RCTs concluded that annual or biennial gFOBT screening had no effect on CRC incidence (in three out of the four studies included in the analysis) but led to an average 16% reduction in CRC-related mortality. The impact of the gFOBT is limited by the poor to moderate sensitivity for advanced adenomas and cancer (table 1). For this reason, gFOBTs are typically used on multiple bowel movements per screening, and are implemented in repeated screening rounds. In contrast, FITs have a higher sensitivity for adenoma and cancer even with a single sample per screening round (table 1). Moreover, unlike gFOBTs, FITs are specific for human globin and do not require dietary restriction. Thus, FIT screening is generally associated with higher participation and higher detection rates of adenomas and CRCs compared with gFOBT screening.

Invasive imaging techniques

Four RCTs showed that a single round of FS screening is associated with a reduction in CRC incidence of 18–23% and CRC mortality of 22–31%. Similar RCTs evaluating colonoscopy are underway, namely the NordICC (NCT00883792), COLONPREV (NCT00906997), SCREEESCO (NCT02078804) and the CONFIRM (NCT01239082) studies. CRC incidence and mortality results from these RCTs are expected between 2025 and 2034.

Colonoscopy is generally considered the gold standard for the detection of colorectal neoplasia. In prospective cohort studies, colonoscopy has been associated with long-term (20–30 years) reduction in CRC mortality. As such, some screening programmes use colonoscopy as the primary screening tool. Other programmes prefer a two-step approach, using colonoscopy only for diagnostic clarification in those with a positive first-line less invasive screening test. The latter approach has, for some countries, the advantages of higher screening uptake and lesser demand on limited colonoscopy resources.

Precursor lesions and cancer can be visualised by CTC, also called virtual colonoscopy. In an average risk population, the per-patient sensitivity of CTC for advanced neoplasia ≥10 mm was 88%. However, this sensitivity decreases for the detection of polyps <10 mm. Compared with stool tests, imaging tests such as CTC are more invasive (making them more burdensome) and costlier.

| Table 1 | Test performance per screening test in asymptomatic, average-risk adults |
|----------------------------------|----------------|----------------|------------|-----------|----------------|
| gFOBT | FIT | FS | CTC | Colonoscopy |
| Sensitivity (%) for detecting advanced neoplasia | 9 to 24 | 32 to 53 | 44 47 49 | 90 to 92 | 88 to 97 | 88 to 96 |
| Sensitivity (%) for detecting CRC | 13 to 50 | 79 | 52 | 90 to 92 | 100 | 92 to 99 |
| Reduction in CRC incidence (%) intention-to-screen | No | Unknown | 18 | Unknown | 69 | 55 |
| Reduction in CRC mortality (%) intention-to-screen | 14 to 16 | 22 | 65 | 28 | 54 | Unknown | 68 |

* Sensitivity is given for the distal colon.
† No CRCs were missed by CTC in six screening trials.
§ No reduction in incidence was found in three of four RCTs included in meta-analysis.
‡ Meta-analysis of observational studies, more results expected.
¶Sensitivity is given for the distal colon.

Colonoscopy is considered the primary diagnostic method to evaluate a positive less invasive screening test, whether that test is based on evaluating stool, serum (blood) or colorectal imaging. The demand and capacity for colonoscopy must be taken into account when a country chooses a screening modality.

**New screening modalities**

Other screening methods have become available for CRC screening. Newer non-invasive tests include DNA, RNA and protein biomarker stool and blood tests. Detection of circulating methylated SEPT9 DNA in blood yielded a CRC sensitivity of 48%, which is at the lower end of the gFOBT range (37–79%). Sensitivity for the detection of advanced adenomas was very low (11%). Biomarker stool tests are based on the principle that colorectal neoplasms shed surface cells in the stool. DNA from these cells can be isolated and tested for the presence of mutations and epigenetic changes acquired during carcinogenesis. Stool DNA testing has improved over the last decade. A recent study incorporating FIT with DNA markers, reported a 92.3% sensitivity for CRC and 42.4% for advanced adenomas, which was significantly higher than FIT at a cut-off of 20 µg Hb/g faeces (100 ng/mL) (sensitivity for cancer 72%, for advanced adenoma 23%). One cautionary note about this study is the difference in positivity rates between the DNA and FIT that were used. Both non-invasive tests are meant to select subjects at a higher risk of neoplasia so they can undergo colonoscopy. In other words, a non-invasive test aims to enrich the population undergoing colonoscopy and relieves those at low risk of neoplasia of the burden and risk of colonoscopy. In this particular study, the investigators used a relatively high FIT cut-off and a more ‘liberal’ DNA cut-off. As a result, the number of persons referred for colonoscopy was more than twice as high after stool DNA testing than after FIT. In further comparisons between non-invasive tests, there is a need to set the cut-off of each test at such a level that both tests yield a similar positivity rate, since this determines colonoscopy demand and thus largely influences the burden and costs of a screening programme.

Newer imaging tests include colon capsule endoscopy (CCE) and magnetic resonance colonography (MRC). CCE is a procedure that uses an ingestible capsule with a camera at each end to produce images of the mucosa during intestinal transit. The average sensitivity of second generation CCE (CCE-2) devices for significant findings (≥6 mm size, or ≥ three polyps irrespective of size) is 86%. When used as a triage test after a positive FIT to determine who should proceed to colonoscopy, CCE has the potential to reduce the number of colonoscopies performed by 71%. In case of an incomplete colonoscopy, the diagnostic yield of CCE has been reported to be superior to that of CTC for polyps ≥6 mm as well as ≥10 mm with colonoscopy as the gold standard. An MRC study performed in 286 asymptomatic individuals reported a sensitivity of 78.4% for adenomas >6 mm. The impact of these new screening modalities on screening uptake and CRC incidence and mortality requires further study.

The efficacy of different screening methods in terms of impact on CRC incidence and mortality is not known. Outlines the performance of different screening tests in an average risk population. For the given rates of reduction in CRC incidence and mortality, results of a single round as well as multiple rounds were included in this table. Advanced neoplasia is defined as an adenoma ≥10 mm, or ≥25% villous component, or with high-grade dysplasia or CRC. More recently, attention has also been drawn to the relevance of larger or dysplastic serrated polyps as potential CRC precursors. The accuracy of individual screening methods in detecting these lesions is under study.

**ORGANISED AND OPPORTUNISTIC SCREENING**

An organised screening programme involves a systematic process of inviting a target population to participate in screening and ensuring follow-up of those with a positive screen. An organised programme should measure and report on the quality of each step in the screening process. The IARC outlines the following elements for organised screening programmes:

- An explicit policy with specified age categories, screening method and screening interval
- A defined target population
- A management team responsible for implementation
- A healthcare team for decisions, care and follow-up of patients with positive screening tests
- A quality assurance structure for every step in the process
- A process for monitoring, evaluating and identifying cancer occurrence in the population.

In organised screening, substantial information technology infrastructure is required to support the programme including systems for invitations, recalls, reminders, tracking of screening results, ensuring follow-up and tracking of clinical outcomes such as cancer incidence, mortality and stage. For tracking of screening results, a set of universally applicable CRC screening measures and indicators have been established. A cancer registry is critical and can be linked to all other relevant databases including laboratories and endoscopic centres. In contrast, opportunistic screening is delivered outside of an organised screening programme on an ad hoc basis usually through fee-for-service reimbursement of physicians. Since organised screening focuses on quality assurance, it provides greater protection against the possible harms of screening including over-screening and underscreening, poor quality, inappropriate use of resources, complications arising from screening and poor follow-up of those with a positive screen.

The approach to screening in the USA is largely opportunistic. The contributions and quality initiatives from many national bodies has been crucial, including the US Preventive Services Task Force (USPSTF), an independent volunteer panel of national experts in prevention and evidence-based medicine that reviews evidence and makes recommendations to guide the choice of CRC screening tests. In addition, multiple professional associations have emphasised the importance of colonoscopy quality in the context of CRC screening. Equity of access to screening in the USA remains uncertain, however.

**Quality assurance**

In 2010, the IARC published the European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. These guidelines outline targets for key performance indicators for CRC screening including participation, follow-up and cancer detection rates. For example, the guidelines recommend that invitation coverage in the target population should be high (95%) and that programmes should aim for participation rates of at least 63%.

Given that at least 10 years are required to plan, pilot and implement a screening programme, the full impact of a nationwide screening programme on indicators such as CRC mortality rates requires long follow-up. Therefore, an intermediate measure may be used to evaluate programme performance, expressed as the number of persons with advanced adenomas with a cut-off of 20 µg Hb/g faeces (100 ng/mL) (sensitivity for cancer 72%, for advanced adenoma 23%). For the given rates of reduction in CRC incidence and mortality, results of a single round as well as multiple rounds were included in this table. Advanced neoplasia is defined as an adenoma ≥10 mm, or ≥25% villous component, or with high-grade dysplasia or CRC. More recently, attention has also been drawn to the relevance of larger or dysplastic serrated polyps as potential CRC precursors. The accuracy of individual screening methods in detecting these lesions is under study.

**Quality assurance**

In 2010, the IARC published the European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. These guidelines outline targets for key performance indicators for CRC screening including participation, follow-up and cancer detection rates. For example, the guidelines recommend that invitation coverage in the target population should be high (95%) and that programmes should aim for participation rates of at least 63%.

Given that at least 10 years are required to plan, pilot and implement a screening programme, the full impact of a nationwide screening programme on indicators such as CRC mortality rates requires long follow-up. Therefore, an intermediate measure may be used to evaluate programme performance, expressed as the number of persons with advanced adenomas with a cut-off of 20 µg Hb/g faeces (100 ng/mL) (sensitivity for cancer 72%, for advanced adenoma 23%). For the given rates of reduction in CRC incidence and mortality, results of a single round as well as multiple rounds were included in this table. Advanced neoplasia is defined as an adenoma ≥10 mm, or ≥25% villous component, or with high-grade dysplasia or CRC. More recently, attention has also been drawn to the relevance of larger or dysplastic serrated polyps as potential CRC precursors. The accuracy of individual screening methods in detecting these lesions is under study.

**Quality assurance**

In 2010, the IARC published the European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. These guidelines outline targets for key performance indicators for CRC screening including participation, follow-up and cancer detection rates. For example, the guidelines recommend that invitation coverage in the target population should be high (95%) and that programmes should aim for participation rates of at least 63%.

Given that at least 10 years are required to plan, pilot and implement a screening programme, the full impact of a nationwide screening programme on indicators such as CRC mortality rates requires long follow-up. Therefore, an intermediate measure may be used to evaluate programme performance, expressed as the number of persons with advanced adenomas with a cut-off of 20 µg Hb/g faeces (100 ng/mL) (sensitivity for cancer 72%, for advanced adenoma 23%). For the given rates of reduction in CRC incidence and mortality, results of a single round as well as multiple rounds were included in this table. Advanced neoplasia is defined as an adenoma ≥10 mm, or ≥25% villous component, or with high-grade dysplasia or CRC. More recently, attention has also been drawn to the relevance of larger or dysplastic serrated polyps as potential CRC precursors. The accuracy of individual screening methods in detecting these lesions is under study.
neoplasia detected per 1000 invited individuals during the screening interval. This measure takes multiple factors into consideration namely participation rate, positivity rate and the positive predictive value for the detection of advanced neoplasia. It is thus a balanced assessment of the overall performance of a screening programme. Table 2 outlines the number of people with advanced neoplasia identified per 1000 invited individuals in those programmes that have published their results. There is marked variation across screening tests and within a screening test type for all indicators. Wide ranges for the gFOBT/FIT-based results may be due to the use of more sensitive tests or more stringent criteria for defining test positivity.

**Cost-effectiveness**

Cost-effectiveness studies for CRC screening have concluded that screening is cost-effective compared with no screening. Microsimulation models can help to identify the most appropriate screening strategy given the available resources and budget constraints. The efficiency frontier will identify strategies that are the most effective in terms of life-years gained relative to the cost of the screening strategy.

Cost-effectiveness studies have shown that screening can also be cost-effective in countries with limited financial resources. However, access to and improvement in CRC treatment may be a higher priority than screening in these settings. Using resources to implement population-based screening in a region with no or very limited access to treatment would not be a cost-effective measure.

**CRC SCREENING PROGRAMMES WORLDWIDE**

Over the past two decades, the range of CRC screening modalities has expanded, and many population-based programmes have been implemented. Nevertheless, large geographical variations remain with respect to implementation of CRC screening (figure 1A–C). As expected screening programmes have been more frequently implemented in Western countries with higher CRC incidence and more available resources. Table 3 shows an overview of screening methods used worldwide grouped into the six WHO regions.

---

**Table 2. Performance of a first round screening programme per screening test, based on screening indicators.**

<table>
<thead>
<tr>
<th>Screening Test</th>
<th>gFOBT</th>
<th>FIT</th>
<th>FS*</th>
<th>CTC</th>
<th>Colonoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation rate (%)</td>
<td>16–47</td>
<td>17–77</td>
<td>30–84</td>
<td>18–34</td>
<td>16–93</td>
</tr>
<tr>
<td>Positivity rate (%)</td>
<td>2.4–6.8</td>
<td>1.1–13</td>
<td>5.3–23</td>
<td>8.6–9.0</td>
<td>4.9–11</td>
</tr>
<tr>
<td>Advanced neoplasia detection rate (%)</td>
<td>29–50</td>
<td>16–43</td>
<td>20–100</td>
<td>54–71</td>
<td>100</td>
</tr>
<tr>
<td>Detected advanced neoplasia per 1000 invited individuals§</td>
<td>2.1–6.3</td>
<td>1.1–21</td>
<td>23–39</td>
<td>8.8–21</td>
<td>14–73</td>
</tr>
</tbody>
</table>

*Relative detected advanced neoplasia per 1000 invited individuals is only for the area of the colon examined by FS.
†Those with a positive screen were recommended colonoscopy (except when colonoscopy was used as the primary screening test), which enabled the determination of the positive predictive value of the primary screen (the proportion of subjects that during colonoscopy were diagnosed with advanced neoplasia). The uptake of the test was multiplied by the positivity rate and positive predictive value to determine the number of true positives identified with advanced neoplasia per 1000 invited.
‡Proportion of subjects with a positive primary screening test that were found to have advanced colorectal neoplasia on secondary screening by colonoscopy.
§Detection rate per screening round.

CTC, CT colonography; FIT, faecal immunochemical test for haemoglobin; FS, flexible sigmoidoscopy; gFOBT, guaiac faecal occult blood test.

---

**Figure 1.** Overview of screening programmes 2014. Regional differences within one country are, except for North-America, not taken into account in these figures. (A) Overview of screening programmes in European region. (B) Overview of screening programmes in region of the Americas. (C) Overview of screening programmes in Western Pacific, South-East Asia and Eastern Mediterranean region. FIT, faecal immunochemical test for haemoglobin; gFOBT, guaiac faecal occult blood test.
European region

Within Europe, the ASRi rates show a fivefold variation, with lowest rates for men and women in the Balkan countries of Bosnia Herzegovina (30 per 100,000 and 19 per 100,000, respectively) and Albania (13 per 100,000 and 11 per 100,000, respectively). Highest incidence rates in men are found in Slovakia, Hungary and the Czech Republic, while highest incidence rates in women are found in Norway, Denmark and The Netherlands. Although CRC mortality rates follow a similar geographical pattern to incidence rates, CRC mortality is also high in some countries with relatively low incidence rates (Moldova, Russia, Montenegro, Poland and Lithuania). A low CRC incidence accompanied by a high CRC mortality can imply limited access to healthcare, and/or suboptimal CRC treatment. It is estimated that in 2015 around 490,000 Europeans will be diagnosed with CRC and 240,000 will die from the disease.

There are large variations among national CRC screening practices in Europe especially since European guidelines for CRC first appeared in 2010. Various screening programmes (pilot, opportunistic or organised) were already in place at that time. There are also considerable differences with respect to financial resources available for screening. The same pertains to colonoscopy capacity, with a more than threefold variation in endoscopy resources across European countries. Taken together, these factors have led to widespread variation. For details by country, see table 3.

Most countries in Europe have implemented an organised screening programme. Nine countries have an opportunistic programme in place, and 16 countries either have or are beginning to implement organised screening (table 3). In 2015, 24 out of 28 European Union countries had established or were preparing a nationwide organised or opportunistic CRC screening programme.
For instance Finland, France, Slovenia and the UK have completed rollout of their organised programmes. In Belgium, The Netherlands, Denmark, Ireland, Italy, Malta, Poland and Spain, rollout is ongoing. Norway, Portugal and Sweden are in the pilot phase.

Some countries have yet to implement a screening programme. For instance, the Greek Hellenic Society of Gastroenterology released guidelines for CRC screening in 2013. Despite previous low uptake and restricted resources, it recommended colonoscopy as the method of choice for CRC screening. Implementation of an organised programme is in a planning phase.

Slovakia has the highest CRC rates in Europe (world ASRi is 43 per 100 000 and age-standardised mortality rate is 18 per 100 000). However, the country does not have a CRC screening programme, despite the Ministry of Health publishing a list of departments performing screening colonoscopy. Further work is needed to move forward with a national screening programme. No population-based CRC screening programme is in place in Bulgaria, Albania, Bosnia and Herzegovina, Kosovo, Macedonia, Montenegro, Romania, Serbia or Russia.

Most European countries with an organised programme screen by means of a non-invasive stool test, in which previously implemented gFOBT based programmes are switching to FIT, such as the UK since 2014 and France since 2015. FS is gradually being introduced in England. As of March 2015, about two-thirds of screening centres were beginning to offer this one-time-only test to 55 year-olds. Countries with an opportunistic programme are sometimes faced with low screening uptake. Such is the case in Austria and the Czech Republic, which has achieved coverage of approximately 25% of the target population.

Organised programmes may also face uptake issues, such as in France and Croatia. In France participation rates were initially 34.3% in the first 2 years, with nearly three million people being screened. Active participation by general practitioners increased the participation up to 50% in some parts of the country. The participation rate in Croatia after 3 years of invitations of about a million people was only 19.9%.

Figure 1 Continued.
**Table 3** Characteristics of screening programmes worldwide, presented alphabetically by country within regions defined by WHO (last updated May 2015)

<table>
<thead>
<tr>
<th>Country</th>
<th>ASRi</th>
<th>ASRm</th>
<th>Region(s)</th>
<th>Programme type</th>
<th>Status of organised programme</th>
<th>Type of test</th>
<th>Definition positive test</th>
<th>Starting year</th>
<th>Age range (years)</th>
<th>Screening interval (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>European region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>26</td>
<td>9.9</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT</td>
<td>1980</td>
<td>40+</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>All</td>
<td>Opportunistic</td>
<td>OC</td>
<td>2005</td>
<td>50+</td>
<td>84–120</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>36.7</td>
<td>11.8</td>
<td>Wallonia and Brussels</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT 15 μg Hb/g</td>
<td>2013</td>
<td>56–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Flanders</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>gFOBT</td>
<td>2009</td>
<td>50–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>66.6</td>
<td>16</td>
<td></td>
<td>Organised</td>
<td>gFOBT</td>
<td>2007</td>
<td>50–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rollout complete</td>
<td>FIT 1/12 slides</td>
<td>2000</td>
<td>50+</td>
<td>120/24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>39.9</td>
<td>15.4</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT</td>
<td>1971</td>
<td>50–54</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>All</td>
<td>Opportunistic</td>
<td>OC/FIT</td>
<td>2002</td>
<td>55+</td>
<td>120/24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>40.5</td>
<td>14.5</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT 20 μg Hb/g</td>
<td>2014</td>
<td>50–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>27.2</td>
<td>12.3</td>
<td></td>
<td>Organised</td>
<td>gFOBT</td>
<td>2005</td>
<td>60–69</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>23.5</td>
<td>8.3</td>
<td>All</td>
<td>Organised</td>
<td>gFOBT</td>
<td>2013</td>
<td>50–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>30</td>
<td>10.2</td>
<td>All</td>
<td>Organised</td>
<td>FIT 30 μg Hb/g</td>
<td>1971</td>
<td>50–54</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>30.9</td>
<td>10.4</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT/Oc</td>
<td>2002</td>
<td>55+</td>
<td>120/24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>13.5</td>
<td>7.5</td>
<td>All</td>
<td>Opportunistic</td>
<td>OC</td>
<td>2009</td>
<td>50–80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hungary</td>
<td>42.3</td>
<td>20.8</td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iceland</td>
<td>28.4</td>
<td>7.4</td>
<td></td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT 45 μg Hb/g</td>
<td>2012</td>
<td>55–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>39.9</td>
<td>10.8</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT 20 μg Hb/g</td>
<td>1982</td>
<td>44–75</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Piedmont/Veneto</td>
<td>Organised</td>
<td>Rollout pilot</td>
<td>FS</td>
<td>1992</td>
<td>58–60</td>
<td>once</td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>23.7</td>
<td>12.9</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT</td>
<td>2005</td>
<td>50+</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>23.4</td>
<td>13.7</td>
<td>Regions</td>
<td>Opportunistic</td>
<td>FIT</td>
<td>2009</td>
<td>50–75</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luxembourg</td>
<td>31.5</td>
<td>11.2</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT/OC</td>
<td>2005</td>
<td>50+</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malta</td>
<td>31.9</td>
<td>12.2</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td>2012</td>
<td>60–64</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>40.2</td>
<td>13.4</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT 47 μg Hb/g</td>
<td>2014</td>
<td>55–75</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>38.9</td>
<td>13</td>
<td>Regions</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>27</td>
<td>14.5</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>OC</td>
<td>2000</td>
<td>50–66</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>31.7</td>
<td>13.6</td>
<td>Centre region</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Romania</td>
<td>26.4</td>
<td>13.4</td>
<td></td>
<td>Organised</td>
<td>gFOBT/OC</td>
<td>2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>42.7</td>
<td>18</td>
<td>All</td>
<td>Opportunistic</td>
<td>gFOBT/OC</td>
<td>2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>37</td>
<td>16.2</td>
<td>All</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT 1/2 samples at 67 μg Hb/g</td>
<td>2007</td>
<td>50–69</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>33.1</td>
<td>12.3</td>
<td>Regions</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td>2000</td>
<td>60–69</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>29.2</td>
<td>10.9</td>
<td>Regions</td>
<td>Organised</td>
<td>gFOBT/OC/FS</td>
<td>2006</td>
<td>50–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>29.4</td>
<td>10.9</td>
<td>Regions</td>
<td>Organised</td>
<td>gFOBT/OC/FS</td>
<td>2007</td>
<td>50–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>16.6</td>
<td>10.0</td>
<td>All</td>
<td>Opportunistic</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td>30.2</td>
<td>10.7</td>
<td></td>
<td>Organised</td>
<td>Rollout complete</td>
<td>gFOBT/FS 5/6 slides*</td>
<td>2000</td>
<td>60–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Rollout ongoing</td>
<td>FIT 20 μg Hb/g</td>
<td>2009</td>
<td>55+60–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scotland</td>
<td>23.4</td>
<td>13.7</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Region of the Americas</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td>23.8</td>
<td>13</td>
<td>Urban areas</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bahamas</td>
<td>20.3</td>
<td>10.8</td>
<td></td>
<td>Opportunistic</td>
<td>gFOBT/OC/FS</td>
<td>2006</td>
<td>60–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbados</td>
<td>28.4</td>
<td>14.1</td>
<td></td>
<td>Opportunistic</td>
<td>gFOBT/OC/FS</td>
<td>2007</td>
<td>50–74</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>15.8</td>
<td>8</td>
<td>Regions/Sao Paulo</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Continued*
To match the number of FIT-positives with the available colonoscopy capacity, the FIT cut-off had to be raised in the Netherlands, Scotland and the Republic of Ireland.\(^95\) \(^96\)

Compliance to colonoscopy following a positive non-invasive screening test can also be an issue. In Lithuania only 52.4% of the FIT-positives undergo colonoscopy; resulting in a very low

### Table 3

<table>
<thead>
<tr>
<th>Country</th>
<th>ASRi</th>
<th>ASRm</th>
<th>Region(s)</th>
<th>Programme type</th>
<th>Status of organised programme</th>
<th>Type of test</th>
<th>Definition positive test</th>
<th>Starting year</th>
<th>Age range (years)</th>
<th>Screening interval (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>35.2</td>
<td>10.8</td>
<td>Ontario</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>gFOBT</td>
<td>1/6 slides</td>
<td>2008</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>British Columbia</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td>1/2 samples at 20 µg Hb/g</td>
<td>2009</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alberta</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td>15 µg Hb/g</td>
<td>2007</td>
<td>50–74</td>
<td>12 or 24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Saskatchewan</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td>20 µg Hb/g</td>
<td>2009</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Manitoba</td>
<td>Organised</td>
<td>Rollout complete Pilot/Planning phase</td>
<td>FIT</td>
<td>1/6 slides</td>
<td>2007</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quebec</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td>FIT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>New Brunswick</td>
<td>Organised</td>
<td>Pilot/Planning phase</td>
<td>FIT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nova Scotia</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td>1/2 samples at 300 µg Hb/g</td>
<td>2009</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Prince Edward Island</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td></td>
<td>2009</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Newfoundland and Labrador</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td></td>
<td>2012</td>
<td>50–74</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Yukon</td>
<td>No screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Northwest territories</td>
<td>No screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nunavut</td>
<td>No screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td>15</td>
<td>8.6</td>
<td>Seven cities</td>
<td>Organised</td>
<td>Pilot</td>
<td>FIT</td>
<td>20 µg Hb/g</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>19.7</td>
<td>11.6</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jamaica</td>
<td>14.4</td>
<td>7.9</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martinique</td>
<td>23.9</td>
<td>9.4</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td>30 µg Hb/g</td>
<td>2007</td>
<td>50–74</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>7.8</td>
<td>4.1</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>24.6</td>
<td>9.6</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trinidad/Tobago</td>
<td>23.5</td>
<td>13.1</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uruguay</td>
<td>29.5</td>
<td>15.7</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>25</td>
<td>9.2</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kaiser Permanente North Carolina</td>
<td>Organised</td>
<td>FIT/OC</td>
<td></td>
<td></td>
<td></td>
<td>50–75</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Veterans Health Administration</td>
<td>Organised</td>
<td>FIT/OC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Pacific, South-East Asia and Eastern Mediterranean region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Armenia</td>
<td>19.3</td>
<td>11.1</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td>38</td>
<td>9</td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td></td>
<td>2003</td>
<td>50–74</td>
<td>60</td>
</tr>
<tr>
<td>Brunei</td>
<td>25</td>
<td>12</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>14.2</td>
<td>7.4</td>
<td>Several including Shanghai and Hangzhou regions</td>
<td>Organised</td>
<td>Pilot</td>
<td>gFOBT/OC</td>
<td></td>
<td>2008</td>
<td>50–74</td>
<td>40–74</td>
</tr>
<tr>
<td>Hong Kong</td>
<td></td>
<td></td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td>35.9</td>
<td>11.1</td>
<td>All</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>FIT</td>
<td></td>
<td>1990</td>
<td>50–74</td>
<td>12</td>
</tr>
<tr>
<td>Japan</td>
<td>32.2</td>
<td>11.9</td>
<td>All</td>
<td>Organised</td>
<td>Rollout complete</td>
<td>gFOBT/FIT/OC</td>
<td></td>
<td>1992</td>
<td>40–69</td>
<td>12</td>
</tr>
<tr>
<td>Jordan</td>
<td>25.6</td>
<td>15.5</td>
<td>Opportunistic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>22.8</td>
<td>12.8</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea, North</td>
<td>21.8</td>
<td>10.7</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea, South</td>
<td>45</td>
<td>12</td>
<td>All</td>
<td>Organised</td>
<td>FIT</td>
<td></td>
<td></td>
<td>2004</td>
<td>50–74</td>
<td>12</td>
</tr>
<tr>
<td>Korea, South</td>
<td>45</td>
<td>12</td>
<td>All</td>
<td>Organised</td>
<td>FIT</td>
<td></td>
<td></td>
<td>2004</td>
<td>50–74</td>
<td>12</td>
</tr>
<tr>
<td>Malaysia</td>
<td>18.3</td>
<td>9.4</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>37</td>
<td>15</td>
<td>Waitemata</td>
<td>Organised</td>
<td>FIT</td>
<td>15 µg Hb/g</td>
<td></td>
<td>2011</td>
<td>50–74</td>
<td>12</td>
</tr>
<tr>
<td>Singapore</td>
<td>33.7</td>
<td>11.8</td>
<td>All</td>
<td>Organised</td>
<td>FIT</td>
<td></td>
<td></td>
<td>2004</td>
<td>50–74</td>
<td>12</td>
</tr>
<tr>
<td>Taiwan</td>
<td></td>
<td></td>
<td>All</td>
<td>Organised</td>
<td>Rollout ongoing</td>
<td>FIT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>12.4</td>
<td>7.3</td>
<td>Lampong Province</td>
<td>Organised</td>
<td>Pilot</td>
<td>200 ng/mL</td>
<td></td>
<td>2011</td>
<td>50–74</td>
<td>65</td>
</tr>
</tbody>
</table>

*Weak positives (one to four of six slides positive) are retested.
†Weak positives (one to four of six slides positive) are retested with FIT.

ASRi, age-standardised incidence rates; ASRm, age-standardised mortality rates; DRE, digital rectal exam; FIT, faecal immunochemical test for haemoglobin; FS, flexible sigmoidoscopy; gFOBT, guaiac faecal occult blood test; OC, (optical) colonoscopy.

Recent advances in clinical practice


on April 7, 2022 by guest. Protected by copyright.http://gut.bmj.com/ Gut: first published as 10.1136/gutjnl-2014-309086 on 3 June 2015. Downloaded from http://gut.bmj.com/ on April 7, 2022 by guest. Protected by copyright.
combined adenoma and CRC detection rate of 1.2% cumulatively over 3 years.97

Region of the Americas
North-America
The ASRi for North America is 26.1 per 100 000 (23 and 30 for women and men, respectively).1 An approximate 136 830 persons have been diagnosed with CRC and 50 310 persons died of the disease in the USA in 2014.98 An additional estimated 24 400 new cases of CRC were diagnosed in Canada in the same year.99 Reimbursement for colonoscopy in these Western countries has facilitated the early adoption of opportunistic screening. For example, previous work in Ontario, Canada demonstrated an increase in colonoscopy use prior to the launch of an organised CRC screening programme in the province in 2008.100

To date, all 10 Canadian provinces have announced, are planning or have implemented organised CRC screening programmes.101 No organised screening programmes have been announced in any of the three territories. Special challenges faced by the territories include a lack of resources/facilities and a low population density across vast areas of land. Most provinces are currently using FIT to screen persons aged 50–74 years at average risk for CRC (figure 1B).102 Ontario’s ColonCancerCheck, Canada’s first organised CRC screening programme, launched province-wide in 2008.102 Participation in the gFOBT aspect of the programme was 29.8% in 2010–2011.102 In Ontario in 2013, 58% of the target population were up-to-date with CRC screening, taking all screening modalities into account. Early aggregate results from the first round of screening (January 2009–December 2011) of five other provincial programmes (British Columbia, Saskatchewan, Manitoba, Nova Scotia and Prince Edward Island) showed a much lower participation rate (16.1%).103 Opportunistic screening colonoscopy is available to a variable extent in most Canadian provinces.

Colorectal cancer screening in the USA is recommended by the USPSTF for persons at average risk (50–75 years old) with annual gFOBT, periodic FS or colonoscopy.104 Data from the annual Behavioural Risk Factor Surveillance System survey revealed that approximately 65% of US adults were up-to-date with CRC screening in 2012, with colonoscopy being the most widely used test.104 The American Cancer Society recently reported that CRC incidence and mortality rates significantly decreased over the past decade.105 This is in particular attributed to CRC screening.106 Enablers for the success of opportunistic screening seen in USA include the quality initiative supported by national GI societies including USPSTF, American Cancer Society, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy and National Colorectal Cancer Roundtable, among others. This has played a significant role in the high uptake of screening in the country. On the other hand, organised screening programmes in various regions of the country have also been established. Two prime examples include the Kaiser Permanente Northern California programme and the Veterans Health Administration programme. Kaiser Permanente Northern California programme participation rates have doubled since 2004 and were 69% in 2010107 while screening rates in the Veterans Health Administration programme among veterans aged 52 years or older were already as high as 68% as early as 2001.108

Mexico has also launched a CRC awareness campaign focusing on gFOBT screening but without much uptake.

Central and South America
Although numerous Central and South American countries have national guidelines in place for CRC screening, very few national screening programmes have been implemented.109–110 The current infrastructure in many countries is lacking to support a full organised screening programme. In addition, very little is done to raise awareness in most regions including Venezuela, Bolivia, Peru, Columbia and Costa Rica. As a result, many of those diagnosed with CRC in these regions are identified after the disease has metastasised.110

For example, in Brazil, screening colonoscopies for those aged 50 years and older have been approved by the Ministry of Health, but uptake remains low.110 Numerous CRC pilot programmes have begun in various municipalities. One example is the programme by the Brazilian Association for Colorectal Cancer Prevention, developed in Sao Paulo.111 Starting in 2006, those 40 years and older at average risk were screened with FIT. Of the 4567 kits that were distributed between August 2006 and March 2007, 79.7% were returned and analysed. Positivity rates were approximately 10.7%.112

Some success was seen with Argentina’s CRC screening programme in urban areas of the country.113 The programme will next be piloted in rural regions of the country.109 In Uruguay, a CRC pilot programme was launched in 1996 for those at average risk. Persons aged 50 years or older were screened with FIT and followed up with colonoscopy.112 Between June 1997 and July 2004, 90.1% of the 11 734 persons enrolled in the CRC screening programme completed a FIT. Of these, 11.1% had a positive test.

Caribbean
Organised screening for CRC is not routinely performed in the Caribbean. Opportunistic screening with colonoscopy is available on some islands.114 However, even with effective screening, many Caribbean countries lack the medical facilities to provide appropriate cancer treatment. As such, organised CRC screening is not a priority. For example, in Jamaica, screening accounts for 11% of the performed colonoscopies.115 Similarly, low uptake of CRC screening has been reported in other countries such as Puerto Rico and Cuba.116

African region
A mathematical modelling study showed that in the sub-Saharan African region, screening for CRC by colonoscopy at age 50 years in combination with treatment can be considered cost-effective.103 However, the need for population-based CRC screening in the low-income countries of Africa is questioned given the overall relatively low burden of disease, the substantial burden of communicable diseases and the limited resources.103

In addition, means by which to identify the target population, availability of colonoscopy and an appropriate number of well trained specialists are lacking in most regions.117

Eastern Mediterranean region
Predictions specific to the Eastern Mediterranean region indicate that generally countries in this part of the world will experience an increase in all cancer mortality of approximately 181% over the next 15 years.118 The current CRC incidence is highest in Israel (36 per 100 000), Jordan (26 per 100 000), Kazakhstan (23 per 100 000), Armenia (19 per 100 000), Syrian Arab Republic (16 per 100 000), Lebanon (16 per 100 000) and the State of Palestine (15 per 100 000). CRC mortality rates are highest in Jordan (16 per 100 000), Kazakhstan (13 per
100,000), Armenia (11 per 100,000) and Israel (11 per
100,000). In Israel, an organised programme for individuals aged 50–74
years has been put in place by the country’s four healthcare pro-
viders with the government establishing national oversight of
provider activities and quality. Insured persons are approached by
their general practitioner for annual FIT screening. In Jordan,
the national health authorities have not yet adopted a specific
strategy or guidelines for CRC screening despite the high preva-
lence of the disease in the country.112 In Middle Eastern coun-
tries that have adopted a Western lifestyle, some opportunistic
programmes are in place. Physicians in the United Arab Emi-
rates have called for countrywide screening but Abu Dhabi
is the only emirate to screen for CRC. The Health Authority
Abu Dhabi advises colonoscopy for people over the age of 40
years. An opportunistic FIT-based pilot study in Qatar
showed a low colonoscopy follow-up rate among those with a
positive FIT of 56%.121

Western Pacific and South-East Asia region

In the Asia Pacific region, CRC incidence varies among regions.
The country with the highest CRC incidence in the world is
Korea (ASR 45 per 100,000). Other countries with high CRC
incidence in Asia are Singapore (ASR 34 per 100,000) and
Japan (ASR 32 per 100,000). There is an alarming rising trend
in CRC incidence and mortality in Asia, especially in Japan,
Korea and China.13 This trend has been explained by changes in
diet and a westernised lifestyle.122 In addition, the overall preva-
lence of advanced colorectal neoplasia in asymptomatic Asian
populations is similar to Western populations.123 The CRC inci-
dence and mortality rates in India (6 per 100,000 and 5 per
100,000, respectively) remain low compared with rising rates in
East Asia.114

Recommendations for CRC screening in the Asia Pacific
region have been published123 and recently updated.13 The Asia
Pacific Colorectal Cancer Working Group recommends CRC
screening in regions where the incidence is high, defined as
greater than 30 per 100,000.13 Recommendations include screen-
ing for those 50–75 years at average risk with a quantita-
tive FIT as the preferred screening method.13 Those with a posi-
tive test result should be referred for colonoscopy. The guidelines
recommend that a clinical risk index can be employed in regions
with limited healthcare resources to prioritise screening
in those at increased risk. Several studies investigated bar-
riers to CRC screening in different cultural and sociopolitical
contexts in the Asia Pacific region. These barriers included poor
knowledge of CRC screening and test characteristics, lack of
financial support and lack of health insurance.126–128

Several countries in the Asia Pacific region have already de-
veloped population-based screening programmes. This includes
China, Japan, Taiwan, Korea and Singapore. In China, those aged
40–74 years are screened with gFOBT and followed up by a
digital rectal exam and colonoscopy. However, the programme
is not available to the entire population and the national registry
used to track clinical outcomes is estimated to capture only 13%
of the country’s population, making planning for healthcare ser-
dices difficult.129 Studies have shown that screening uptake
in China is low and varies widely.129 In Japan, a CRC screening
programme has been in place since 1992 for national health
insurance beneficiaries.67 Individuals aged 40–69 years with
national health insurance are offered screening with FIT. In
2010, participation rates for those aged 40–69 years were 28.1% for
men and 23.9% for women.131 Nationwide CRC screening was
introduced in the Republic of Korea in 2004. The National
Cancer Screening Program sends invitation letters to the target
population at the beginning of the year advising them to get
screened with annual FIT, while those with a positive test are
offered follow-up with colonoscopy or double contrast barium
enema.63 69 Published results from the programme show an
increase in participation rates since launch (10.5% in 2004 to
21.1% in 2008) and a decline in positivity rates from 8.0% to
6.8%.85 Opportunistic screening is also available in the region.

In other regions, such as Hong Kong, community-based
screening programmes have been piloted to evaluate the feasibil-
ity of a large population-based organised screening programme.
Similarly in New Zealand, a 4-year CRC screening pilot began
in late 2011 to determine whether a screening programme
should be rolled out nationally. The pilot results will inform the
decision regarding implementation of a national population-
based screening programme. In Thailand, an organised pilot
programme based on FIT screening has been implemented in
April 2011. It focuses on persons aged 50–65 years in the
Lampang Province. Preliminary results from the pilot show
participation rates of 62.9% among the 127,301 persons in the
target population.65

In Australia, a pilot started in 2002. In 2006, the National
Bowel Cancer Screening Program began providing biennial FIT
(New Hem Tube) to people turning 55 years and 65 years. The
programme will continue to expand between 2015 and 2020 to
fully implement biennial screening for all Australians aged 50–
74 years.132 In other regions, such as in Malaysia, no organised
population-based screening programme exists despite published
guidelines for CRC screening.133

CONCLUSION

CRC incidence and mortality rates vary widely among conti-
nents and within continents. High-quality incidence and mortal-
ity data allow understanding of disease and are thus the first
esential step for effective cancer control planning. In consid-
ering whether to move forward with a CRC screening pro-
gramme, the local impact of the disease relative to other health
problems and the capacity to treat the disease adequately should
be taken into account. Non-communicable diseases as CRC are
rapidly becoming the leading healthcare problem in middle-income
and low-income countries. This in particular pertains to those countries that are transitioning to Western life-
styles and have aging populations. Therefore, the need to con-
sider implementing CRC screening beyond the countries in
which it is currently taking place is likely to increase over time.
Most countries with a high CRC incidence however, already
have some form of screening in place.

Despite major changes over the past 15 years, there remain
many countries without population-based CRC screening
despite high CRC incidence and mortality. This is in most cases
explained by limitations in resources including colonoscopy cap-
acity, and the organisation of structure of healthcare delivery.
Some countries without an existing programme already have
CRC screening on the agenda. This will likely result in imple-
mentation of CRC screening in the coming years.

Most organised CRC screening programmes use non-invasive
stool tests (FIT or gFOBT), whereas most opportunistic pro-
grammes are based on endoscopy, in particular colonoscopy. For
both screening strategies, levels of screening uptake vary consid-
erably throughout the world. A screening strategy should be
chosen carefully to meet the needs of the applicable screening
scenario. A comprehensive understanding of the full range of
screening modalities and strategies available for CRC screening


1646

Published online as 10.1136/gutjnl-2014-309086 on 3 June 2015. Downloaded from http://gut.bmj.com/ on April 7, 2022 by guest. Protected by copyright.
is needed for appropriate selection of strategies relative to available financial resources and colonoscopy capacity.

The lack of CRC screening in many countries and the low screening uptake in various others provide room for improvement. In countries with a CRC screening programme with low uptake levels, targeted actions need to be considered to improve uptake. This may include adaptations to the invitation and follow-up protocol, in particular implementing an active call-back recall system. Other measures may include a change to or addition of another screening modality. Professional gastroenterology associations may actively promote such changes in close conjunction with health authorities and screening organisations.

Finally, quality assurance and evaluation is of paramount importance to ensure optimal impact, minimal burden and balanced use of resources. Therefore, screening measures and quality indicators should be reported, allowing national evaluation and international comparison to improve CRC screening quality.

In conclusion, the global challenge is to evaluate the need for CRC screening in a given jurisdiction or country, and, if indicated, to develop a tailored CRC screening programme for which the uptake is high. This is especially necessary for low resource countries that face an increase in CRC incidence, as populations adopt a more Westernised lifestyle.

Author affiliations
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong, Hong Kong
Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia

Contributors EJK designed and conceptualised the outline of the paper. The manuscript was drafted by EHS and AR. All coauthors provided critical revision for important intellectual content.

Competing interests We have read and understood BMJ policy on declaration of interests and declare the following interests: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. GPy chairs the Scientific Advisory Board for Clinical genomics but none of their products are referred to in this manuscript.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES
14 World Endoscopy Organization. WEO Colorectal Cancer Screening Committee. WEO/OMED, 2015.
Recent advances in clinical practice


